Correlation of Toxicities and Efficacies of Pemetrexed with Clinical Factors and Single-nucleotide Polymorphisms: a Prospective Observational Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Aug 26

PMID 37633908

Authors

Yuichiro Takeda

Go Naka

Yuki Katsuya

Konomi Kobayashi

Manabu Suzuki

Masao Hashimoto

Satoshi Hirano

Yukari Uemura

Affiliations

Soon will be listed here.

Abstract

Background: Pemetrexed is an efficacious multi-targeted antifolate with acceptable toxicity for non-squamous non-small cell lung cancer (non-Sq NSCLC) and malignant pleural mesothelioma. Vitamin B12 and folic acid as premedication can reduce the frequency of severe toxicities of pemetrexed chemotherapy. However, adverse effects are frequent in clinical settings. In this study, we aimed to identify the clinical factors and single-nucleotide polymorphisms (SNPs) associated with the toxicity and efficacy of pemetrexed chemotherapy.

Methods: This observational study was conducted from October 2012 to December 2019; we evaluated the toxicities and efficacies of pemetrexed chemotherapy using multivariate logistic or Cox regression analysis. In total, 106 patients received pemetrexed chemotherapy. SNPs were analyzed for four patients with malignant pleural mesothelioma and 67 with non-Sq NSCLC.

Results: The median progression-free survival (PFS) and overall survival of 63 patients with non-Sq NSCLC, excluding four in the adjuvant setting, were 6.8 and 33.3 months, respectively. Per propensity-score-adjusted multivariate Cox analyses, favorable factors for PFS were folic acid level ≥ 9.3 ng/mL before premedication, platinum combination, bevacizumab combination, vitamin B12 level < 1136 pg/mL before chemotherapy, A/A + A/G of BHMT (742 G > A), and A/A + A/C of DHFR (680 C > A). Favorable prognostic factors included good performance status, low smoking index, body mass index ≥ 20.66 kg/m, folic acid level ≥ 5.55 ng/mL before premedication, higher retinol-binding protein before chemotherapy, and A/G of MTRR (66 A > G). Among the 71 patients who were analyzed for SNPs, the frequencies of hematologic toxicities and non-hematologic toxicities in Grades 3-4 were 38% and 36.6%, respectively. Per propensity-score-adjusted multivariate logistic analyses, risk factors for Grades 3-4 hematologic toxicities were vitamin B12 level < 486 pg/mL before premedication, leucocyte count < 6120 /µL before chemotherapy, folic acid level < 15.8 ng/mL before chemotherapy, status with a reduced dose of chemotherapy, and C/T + T/T of MTHFR (677 C > T). Risk factors for Grades 2-4 non-hematologic toxicities were homocysteine levels ≥ 11.8 nmol/mL before premedication, transthyretin level < 21.5 mg/dL before chemotherapy, C/C + T/T of MTHFR (677 C > T), and A/A + G/G of SLC19A1 [IVS2 (4935) G > A].

Conclusion: The information on metabolites and SNPs of the folate and methionine cycle will help predict the toxicities and efficacies of pemetrexed.

Trial Registration: This trial was retrospectively registered with the University hospital Medical Information Network (UMIN000009366) on November 20, 2012.

References

Niyikiza C, Hanauske A, Rusthoven J, Calvert A, Allen R, Paoletti P . Pemetrexed safety and dosing strategy. Semin Oncol. 2003; 29(6 Suppl 18):24-9. DOI: 10.1053/sonc.2002.37465. View

Niyikiza C, Baker S, Seitz D, Walling J, Nelson K, Rusthoven J . Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002; 1(7):545-52. View

Kawazoe H, Yano A, Ishida Y, Takechi K, Katayama H, Ito R . Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. PLoS One. 2017; 12(2):e0171066. PMC: 5291448. DOI: 10.1371/journal.pone.0171066. View

Huang M, Tsai J, Shen M, Chou S, Yang C . Pemetrexed as a possible cause of severe rhabdomyolysis in the treatment of lung cancer. Lung Cancer. 2012; 76(3):491-2. DOI: 10.1016/j.lungcan.2012.02.009. View

Vootukuru V, Liew Y, Nally Jr J . Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol. 2006; 23(3):419-22. DOI: 10.1385/MO:23:3:419. View

Adjei A, Mandrekar S, Dy G, Molina J, Adjei A, Gandara D . Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2009; 28(4):614-9. PMC: 2815996. DOI: 10.1200/JCO.2009.23.6406. View

Adjei A, Salavaggione O, Mandrekar S, Dy G, Allen Ziegler K, Endo C . Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol. 2010; 5(9):1346-53. PMC: 5735419. DOI: 10.1097/JTO.0b013e3181ec18c4. View

Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S . Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer.... Cancer Chemother Pharmacol. 2014; 74(6):1149-57. DOI: 10.1007/s00280-014-2589-3. View

Jung M, Lee C, Park H, Lee J, Kang Y, Kim S . Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J. 2013; 54(4):854-64. PMC: 3663241. DOI: 10.3349/ymj.2013.54.4.854. View

10.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

11.

Fukuda S, Oguri T, Kunii E, Sone K, Uemura T, Takakuwa O . A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer. Lung Cancer. 2016; 102:15-20. DOI: 10.1016/j.lungcan.2016.10.006. View

12.

Shi Q, Zhang Z, Li G, Pillow P, Hernandez L, Spitz M . Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. Pharmacogenet Genomics. 2005; 15(8):547-55. DOI: 10.1097/01.fpc.0000170916.96650.70. View

13.

Sharma R, Hoskins J, Rivory L, Zucknick M, London R, Liddle C . Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res. 2008; 14(3):817-25. DOI: 10.1158/1078-0432.CCR-07-0425. View

14.

da Costa K, Kozyreva O, Song J, Galanko J, Fischer L, Zeisel S . Common genetic polymorphisms affect the human requirement for the nutrient choline. FASEB J. 2006; 20(9):1336-44. PMC: 1574369. DOI: 10.1096/fj.06-5734com. View

15.

Molloy A, Pangilinan F, Mills J, Shane B, ONeill M, McGaughey D . A Common Polymorphism in HIBCH Influences Methylmalonic Acid Concentrations in Blood Independently of Cobalamin. Am J Hum Genet. 2016; 98(5):869-882. PMC: 4863564. DOI: 10.1016/j.ajhg.2016.03.005. View

16.

Takeda Y, Kusaba Y, Tsukita Y, Uemura Y, Miyauchi E, Yamamoto T . The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study. Clin Transl Radiat Oncol. 2022; 37:57-63. PMC: 9440238. DOI: 10.1016/j.ctro.2022.08.010. View

17.

Kitazawa H, Takeda Y, Naka G, Sugiyama H . Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients. Sci Rep. 2019; 9(1):19872. PMC: 6934749. DOI: 10.1038/s41598-019-56431-w. View

18.

Weisberg I, Park E, Ballman K, Berger P, Nunn M, Suh D . Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis. 2003; 167(2):205-14. DOI: 10.1016/s0021-9150(03)00010-8. View

19.

Xu Y, Yan C, Hao Z, Zhou J, Fan S, Tai S . Association between BHMT gene rs3733890 polymorphism and cancer risk: evidence from a meta-analysis. Onco Targets Ther. 2016; 9:5225-33. PMC: 5001659. DOI: 10.2147/OTT.S103901. View

20.

Li K, Rivory L, Clarke S . Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. Br J Cancer. 2007; 97(8):1071-6. PMC: 2360430. DOI: 10.1038/sj.bjc.6603995. View